University of Miami (Data Collection AND Specimen Analysis Only)
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chandhok, Namrata
NCI-2019-03057, NCT03953898: Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

Active, not recruiting
2
14
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
01/24
11/25
NCT05024994: A Study of E7820 in People With Bone Marrow (Myeloid) Cancers

Active, not recruiting
2
12
US
E7820
Memorial Sloan Kettering Cancer Center, Eisai Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
08/25
08/25
NCT06456463: A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

Recruiting
2
76
US, RoW
Tagraxofusp, Tag, Venetoclax, Ven, Azacitidine, Aza
Stemline Therapeutics, Inc.
Acute Myeloid Leukemia
02/28
02/30
NCT04365179: Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML

Recruiting
1
18
US
Nerofe
Immune System Key Ltd, University of Miami Sylvester Comprehensive Cancer Center
Advanced MDS, AML
06/25
08/25
NCT04477291: A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

Active, not recruiting
1
80
US
CG-806
Aptose Biosciences Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
12/24
05/25
SX682-MDS-102, NCT04245397: Study of SX-682 Alone and in Combination with Oral or Intravenous Decitabine in Subjects with Myelodysplastic Syndrome

Recruiting
1
151
US
SX-682, Decitabine, DEC-C
Syntrix Biosystems, Inc., H. Lee Moffitt Cancer Center and Research Institute, National Heart, Lung, and Blood Institute (NHLBI), AdventHealth, Emory University, University of Miami, Mayo Clinic, Montefiore Medical Center, National Cancer Institute (NCI), Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Myelodysplastic Syndromes
03/28
03/29

Download Options